GLP-1s As A Treatment for Alzheimer's Disease - James Breaks Down the Science
8m | Oct 9, 2026In this episode of the Gillett Health Podcast, James O'Hara, NP , breaks down the latest evidence surrounding
GLP-1 receptor agonists (like semaglutide) and their potential role in Alzheimer's disease and long-term
cognitive health.
While recent clinical trial results show that oral semaglutide does not reverse established Alzheimer's dementia,
could GLP-1s still play a powerful role in preventing cognitive decline?
Key Topics Covered:
Top-line trial results for oral semaglutide in Alzheimer's disease
Observational data showing lower cognitive risk in diabetics on GLP-1s
Changes in the blood biomarker p-tau217
How reducing cravings for sugar, alcohol, and nicotine protects cognitive reserve
Timestamps:
0:00 - Welcome & Introduction
0:38 - GLP-1s and Failed Alzheimer's Reversal Trials
1:22 - Observational Data & PTOW-217 Biomarker
2:21 - Can GLP-1s Be Used for Alzheimer's Prevention?
3:33 - Lifestyle, Cravings, & Risk Factor Reduction
4:48 - Diet Quality Impact & Final Thoughts
Advertising Inquiries: https://redcircle.com/brands
Privacy & Opt-Out: https://redcircle.com/privacy
